HSPA5 and glioblastoma: Taken together, clinical data reveal GRP78 expression not only increases tumor aggressiveness, but also shows upregulation in recurrent GBM in response to cytotoxic drugs, making GRP78 an attractive target for therapy as well as implicating it as a prognostic marker.